跳到主要內容

臺灣博碩士論文加值系統

(100.26.196.222) 您好!臺灣時間:2024/02/26 17:03
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:張豐鵬
研究生(外文):Feng-Peng Chang
論文名稱:肝臟生長因子受體在細胞遭受壓力下之啟動子表現調節
論文名稱(外文):Promoter Activity of Hepatocyte Growth Factor Receptor in Hepatocytes Responding to Cellular Stress
指導教授:林志生林志生引用關係
指導教授(外文):Chih-Sheng Lin
學位類別:碩士
校院名稱:國立交通大學
系所名稱:生物科技系所
學門:生命科學學門
學類:生物科技學類
論文種類:學術論文
論文出版年:2006
畢業學年度:94
語文別:英文
論文頁數:88
中文關鍵詞:肝臟生長因子受體啟動子轉染體外實驗模式報導基因
外文關鍵詞:hepatocyte growth factor receptorpromotertransfectionin vitro modelreporter gene
相關次數:
  • 被引用被引用:0
  • 點閱點閱:165
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
肝損害是國人常見的健康問題也是最普遍因服用藥物而引起的器官毒性。目前已經有很多藥物被認為具有潛在的肝毒性而退出臨床上的應用。因此在人體服用前先行評估化學藥品對肝臟造成的影響並且建立一套完整的藥物毒性檢測系統便是一個重要的過程。過去的研究指出肝細胞生長因子(hepatocyte growth factor)與肝細胞生長因子受體(c-Met)的訊息傳遞在肝臟的生長與修復過程中扮演關鍵性的角色。因此本實驗的目的便是發展一體外(in vitro)的實驗模式,探討肝臟損傷中c-Met的表現調節。
本研究中,我們先從NCBI資料庫中取得人類c-Met 啟動子(promoter)序列,並且在含有luciferase或是enhanced green fluorescent protein等報導基因(reporter gene)的質體(plasmid)中構築322、649和952 bp等片段長度的c-Met promoter。接下來便將建構好的plasmid利用微脂體(liposome)轉染到大鼠正常肝臟細胞株(clone 9)。當promoter經RNA聚合酶結合進行轉錄作用時reporter gene的轉錄作用亦會被啟動。藉此我們便藉由冷光或螢光的訊號瞭解化合物在肝細胞中對c-Met promoter的表現調節情形。
經過plasmid轉染後我們發現322、649和952 bp的c-Met promoter在大鼠細胞中會被辨識,因此我們認為在人類與大鼠的c-Met promoter序列中有保留序列參與了c-Met的表現調節。為了瞭解clone 9細胞株在肝毒性藥物的影響下對c-Met基因的轉錄調節影響。我們分別對細胞處理半致死濃度的acetaminophen、D-galactosamine及thioacetamide等肝毒性藥物。實驗結果顯示20 mM acetaminophen, 60 mM D-galactosamine及150 mM thioacetamine均會顯著的抑制細胞中0.9 met-Luc的表現。因此我們推測在肝毒性藥物的刺激下會使c-Met的表現量下降,而c-Met的下降調節(downregulation)會減少與其配體(ligand)HGF的結合,進而降低肝細胞修復與再生的訊息傳遞。而在RT-PCR的實驗中,不管是正常或是肝損傷的細胞我們並沒有觀察到HGF的表現,但過去的研究指出HGF會由其他器官分泌藉由血液傳至肝臟細胞中,這不但可以說明我們的實驗結果,也指出肝損傷細胞其修復與再生的能力下降不僅是缺乏HGF的表現還包括了c-Met的表現量下降。因此我們認為不管HGF的表現量如何c-Met的調節作用的確可以當作一個生物指標(biomarker)來探討肝臟細胞受損的情形。
此外過去的研究也顯示在消化道腫瘤、黑色素瘤及肉瘤等癌細胞組織中c-Met gene會過量表現(overexpressin)。實驗的證據也指出c-Met gene overexpression最主要是因為基因不正常的轉錄調節所引起。而在我們的實驗中,我們發現MNNG、EMS等致癌物質均會顯著的增加細胞中0.9 met-Luc的表現。這不但與過去的研究相符合的,也指出我們的系統在未來也可以應用在致癌物質的篩選。
本研究已成功的建立了一套以冷光和螢光訊號來分析肝毒性藥物的系統。這個以細胞調節功能為分析基礎的系統可以當作一個藥物篩選平台來檢測可能具有潛在的肝毒性與致癌性物質。未來我們希望這樣的體外模式實驗能在藥物毒性篩選的研究中提供有用的科學資訊。
Liver damage is the most common organ toxicity caused by drugs and is a major health problem. Many drugs have been withdrawn from clinical use because of being recognized as potential hepatotoxins. The evaluation of the hepatic effects of a chemical before human exposure consequently represents a critical step and in vitro hepatotoxicity test is an important procedure of the pilot and high-throughput assay system. It has been demonstrated that hepatocyte growth factor/c-Met (hepatocyte growth factor receptor) signaling pathway is required for efficient liver regeneration and repair. Therefore, the aim of the present study is to develop an experimental in vitro model to study c-Met expression for hepatocyte poisoning.
In this study, human c-Met promoter-Luc (luciferase) and c-Met promoter-EGFP (enhanced green fluorescent protein) were constructed by cloning 322-, 649-, and 952-bp of the 5�S-flanking sequence of human c-Met into the promoterless Luc and EGFP-containing plasmid vector. We made use of a Rattus norvegicus normal liver cell line (clone 9) that expresses a recombinant luciferase or EGFP gene fused to c-Met promoter gene. Consequently, turning on the promoter gene causes the reporter gene to be turned on. Activation or suppression of the promoter gene by chemicals lead to production of reporter signal that ultimately generate fluorescence or luminescence.
By transfection of 0.9, 0.6, 0.3 met-Luc/EGFP, we have clearly suggested that potential regulatory elements conserved between human and rat are likely to be actively involved in transcriptional regulation of the c-Met gene. To understand the hepatotoxic effect on transcriptional regulation of c-Met expression in clone 9 cells, the clone 9 cells were treated with LC50 concentration of acetaminophen, D-galactosamine, and thioacetamide. The results have shown that 20 mM acetaminophen, 60 mM D-galactosamine and 150 mM thioacetamine significantly reduced the c-Met promoter activity in the clone 9 cells harboring 0.9 met-Luc. Our results suggest that after hepatotoxic drugs-treated cells, downregulation of c-Met gene is crucial to regenerate because it decreases the activity of this receptor/ligand system with a lower targeting HGF action. In addition, the HGP expression was not detectable in the clone 9 cells treated with acetaminophen or not by the RT-PCR in this study. However, it is known that other organs can supply this protein to the liver through blood, which may account for its high levels in plasma of hepatitis patients. Therefore, it is reasonable to suggest that the unresponsiveness of hepatotoxic drugs-treated cells to the regeneration-promoting action of HGF may be due not to the lack of HGF, but rather to the lack of expression in the liver of the c-Met protooncogene coding for the HGF receptor. Our study suggests that regardless of the level of liver HGF, c-Met protooncogene seems the most active modulator of liver cell proliferation, and its induction might be a critical factor in determining the site specificity of the receptor/ligand system and might be a useful prognostic marker for evaluating liver poisoning.
Furthermore past studies have shown that c-Met gene is overexpressed in a variety of neoplastic tissues such as carcinomas of the gastrointestinal tract, melanomas, and sarcomas. Experimental evidence suggests that overexpression of the c-Met gene is mainly due to aberrant transcriptional regulation. In this study we found that carcinogenic compounds such as MNNG and EMS significantly increaseed the c-met promoter activity in the clone 9 cells harboring 0.9 met-Luc. Our observation is in complete agreement with a past study that c-Met oncogen was activated after mutagen treatment in vitro [Park et al., 1986]. Hence we believe that this system can also be used to screen carcinogens.
In the present study, we have developed luciferase and EGFP-base assays for the rapid screening of compounds possessing hepatotoxic or carcinogenic properties. This cell-based functional assay could provide a platform for identifying agents with potential hepatotoxic and carcinogenic activity. We hope that the results presented here will serve to accelerate the use of living cells in screens for drug discovery. The ultimate goal of in vitro experiments is to generate the type of scientific information needed to identify compounds that are potentially hepatotoxic or carcinogenic properties. For this purpose, both the design of the experiments and the interpretation of the results are critical.
Content
Chinese Abstract ……………………………………………………………………...... i
English Abstract ………………………………………………………………………... iii
Content …………………………………………………………………………………. vi
Content of Figures ……………………………………………………………………... ix
Content of Tables……………………………………………………………………...... xi
I. Research Background and Significance…………………………….......................... 1
1-1. In vitro models to study hepatotoxicity …………………………………………….. 1
1-2. Screening of cytotoxic compounds …………………………………………………. 2
1-3. Screening of genotoxic compounds…………………………………………………. 4
1-4. The relationship between liver regeneration and hepatocyte growth factor receptor, c-Met………………………………………………………………………………... 5
1-5. C-Met: structures and functions……………………………………………………... 7
1-6. Development of a fluorescence and luminescence-based assay to screen of potential hepatotoxicity compounds………………………………………………... 9
1-7. Characterization of the hepatotoxicity drug in this study …………………………... 15
1-8. Characterization of the hepatoprotective drug, silymarin………………………........ 18
1-9. Characterization of the genotoxic compounds………………………………………. 20
II. Material and Methods………………………………………………………………. 31
2-1. Reagents …………………………………………………………………………….. 31
2-2. Cell lines and culture medium………………………………………………………. 31
2-3. MTT assay ………………………………………………………………………….. 32
2-4. RNA isolation ………………………………………………………………………. 33
2-5. Reverse transcription-polymerase chain reaction (RT-PCR)………………………... 33
2-6. Construction of promoter activity plasmids…………………………………………. 34
2-7. DNA Transfection………………………………………………………………….... 36
2-8. Measurement of enhanced green fluorescent protein (EGFP)…………………….... 37
2-9. Measurement of luciferase expression…………………………………………......... 37
2-10. Flow cytometry analysis of the EGFP reporter ……………………………………. 38
2-11. Immunofluorescence and confocal analysis ……………………………………... 38
2-12. Western blot assay ……………………………………………………………......... 39
2-13. Statistical analysis …………………………………………………………………. 40
III. Results and Discussion……………………………………………………………... 43
3-1. Verification of constructed plasmid…………………………………………………. 43
3-2. Promoter activity assay…………………………………………………………........ 43
3-3. Evaluation of hepatotoxicity effects on cell viability using MTT test ………….... 44
3-4. Evaluation of hepatoprotective of silymarin on clone 9 cells treated with acetaminophen using MTT test……………………………………………………... 45
3-5. Expression of the mRNA level of c-Met in the clone 9 cells treated with acetaminophen………………………………………………………………………. 46

3-6. Inhibition expression of EGFP–expressing clone 9 cells by acetaminophen treatment……………………………………………………………………………..
48
3-7. Confocal microscopy analysis of the EGFP-expressing clone 9 cells treated with acetaminophen………………………………………………………………………. 48
3-8. Flow Cytometry analysis of the EGFP-expressing clone 9 cells treated with acetaminophen………………………………………………………………………. 49
3-9. Development of a luminescence method for the rapid and sensitivity detection of hepatotoxicity drugs…………………………………………………………………
50
3-10. Confocal microscopy analysis of the protein level of the c-Met in clone 9 cells following acetaminophen treatment……………………………………………….. 51
3-11. Evaluation of the possible adverse effect of Chinese herbs on liver………………. 51
3-12. Analysis of the c-Met promoter activity in clone 9 cells treated with MNNG or EMS by luminescence assay………………………………………………………. 52
Conclusions………………………………………………………………………….. 74
References…………………………………………………………………………….. 76
Althaus FR, Lawrence SD, Sattler GL, Longfellow DG, Pitot HC. 1982. Chemical quantification of unscheduled DNA synthesis in cultured hepatocytes as an assay for the rapid screening of potential chemical carcinogens. Cancer Res 42:3010-3015.
Artigiani S, Comoglio PM, Tamagnone L. 1999. Plexins, semaphorins, and scatter factor receptors: a common root for cell guidance signals? IUBMB Life 48:477-482.
Ballal NR, Goldknopf IL, Goldberg DA, Busch H. 1974. The dynamic state of liver nucleolar proteins as reflected by their changes during administration of thioacetamide. Life Sci 14:1835-1845.
Ballet F. 1997. Hepatotoxicity in drug development: detection, significance and solutions. J Hepatol 26(Suppl. 2):26-36.
Barker EA, Smuckler EA. 1972. Altered microsome function during acute thioacetamide poisoning. Mol Pharmacol 8:318-326.
Batakov EA. 2001. Effect of Silybum marianum oil and legalon on lipid peroxidation and liver antioxidant systems in rats intoxicated with carbon tetrachloride. Eksp Klin Farmakol 64:53-55.
Berry DA. 1991. Experimental design for drug development: a Bayesian approach. J Biopharm Stat 1:81-101.
Biour M, Poupon R, Grange JD, Chazouilleres O, Levy VG, Bodin F, Cheymol G. 1993. [Hepatotoxicity of drugs. An updated bibliographic database of liver disorders and responsible drugs]. Gastroenterol Clin Biol 17:H86-115.
Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. 2001. Drug-induced liver injury: mechanisms and test systems. Hepatology 33:1009-1013.
Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. 1995. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376:768-771.
Blechinger SR, Warren JT, Jr., Kuwada JY, Krone PH. 2002. Developmental toxicology of cadmium in living embryos of a stable transgenic zebrafish line. Environ Health Perspect 110:1041-1046.
Bobek V, Plachy J, Pinterova D, Kolostova K, Boubelik M, Jiang P, Yang M, Hoffman RM. 2004. Development of a green fluorescent protein metastatic-cancer chick-embryo drug-screen model. Clin Exp Metastasis 21:347-352.
Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM. 1998. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391:285-288.
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. 1991. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802-804.
Burke MD, Schreiber SL. 2004. A planning strategy for diversity-oriented synthesis. Angew Chem Int Ed Engl 43:46-58.
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. 1992. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629-641.
Butterworth BE, Smith-Oliver T, Earle L, Loury DJ, White RD, Doolittle DJ, Working PK, Cattley RC, Jirtle R, Michalopoulos G, et al. 1989. Use of primary cultures of human hepatocytes in toxicology studies. Cancer Res 49:1075-1084.
Chakrabartty PK, Schneider WC. 1978. Increased activity of rat liver messenger RNA and of albumin messenger RNA modulated by thioacetamide. Cancer Res 38:2043-2047.
Chan AM, King HW, Deakin EA, Tempest PR, Hilkens J, Kroezen V, Edwards DR, Wills AJ, Brookes P, Cooper CS. 1988. Characterization of the mouse met proto-oncogene. Oncogene 2:593-599.
Chang JC, Taylor PB, Leach FR. 1981. Use of the Microtox assay system for environmental samples. Bull Environ Contam Toxicol 26:150-156.
Chojkier M, Fierer J. 1985. D-Galactosamine hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice. Gastroenterology 88:115-121.
Choy G, Choyke P, Libutti SK. 2003. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging 2:303-312.
Chrungoo VJ, Singh K, Singh J. 1997. Silymarin mediated differential modulation of toxicity induced by carbon tetrachloride, paracetamol and D-galactosamine in freshly isolated rat hepatocytes. Indian J Exp Biol 35:611-617.
Comoglio PM. 1993. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. Exs 65:131-165.
Comoglio PM, Boccaccio C. 1996. The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells 1:347-354.
Comoglio PM, Tamagnone L, Boccaccio C. 1999. Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth. Exp Cell Res 253:88-99.
Cronin MT. 2001. Prediction of drug toxicity. Farmaco 56:149-151.
Dambach DM, Andrews BA, Moulin F. 2005. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol 33:17-26.
De Wet JR, Wood KV, Helinski DR, De Luca M. 1985. Cloning of firefly luciferase cDNA and the expression of active luciferase in Escherichia coli. Proc Natl Acad Sci USA 82:7870-7873.
Decker K, Keppler D. 1972. Galactosamine induced liver injury. Prog Liver Dis 4:183-199.
Decker K, Keppler D. 1974. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev Physiol Biochem Pharmacol 71:77-106.
Dehmlow C, Erhard J, de Groot H. 1996. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23:749-754.
D'Errico A, Fiorentino M, Ponzetto A, Daikuhara Y, Tsubouchi H, Brechot C, Scoazec JY, Grigioni WF. 1996. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology 24:60-64.
Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM. 1991. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6:1997-2003.
Donnelly PJ, Walker RM, Racz WJ. 1994. Inhibition of mitochondrial respiration in vivo is an early event in acetaminophen-induced hepatotoxicity. Arch Toxicol 68:110-118.
Duh FM, Scherer SW, Tsui LC, Lerman MI, Zbar B, Schmidt L. 1997. Gene structure of the human MET proto-oncogene. Oncogene 15:1583-1586.
Dyroff MC, Neal RA. 1983. Studies of the mechanism of metabolism of thioacetamide s-oxide by rat liver microsomes. Mol Pharmacol 23:219-227.
Eckl PM, Strom SC, Michalopoulos G, Jirtle RL. 1987. Induction of sister chromatid exchanges in cultured adult rat hepatocytes by directly and indirectly acting mutagens/carcinogens. Carcinogenesis 8:1077-1083.
Galanos C, Freudenberg MA, Reutter W. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 76:5939-5943.
Graves AL, Boyd WA, Williams PL. 2005. Using transgenic Caenorhabditis elegans in soil toxicity testing. Arch Environ Contam Toxicol 48:490-494.
Greene EA, Codomo CA, Taylor NE, Henikoff JG, Till BJ, Reynolds SH, Enns LC, Burtner C, Johnson JE, Odden AR, Comai L, Henikoff S. 2003. Spectrum of chemically induced mutations from a large-scale reverse-genetic screen in Arabidopsis. Genetics 164:731-740.
Greer LF, 3rd, Szalay AA. 2002. Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence 17:43-74.
Guguen-Guillouzo C, Clement B, Baffet G, Beaumont C, Morel-Chany E, Glaise D, Guillouzo A. 1983. Maintenance and reversibility of active albumin secretion by adult rat hepatocytes co-cultured with another liver epithelial cell type. Exp Cell Res 143:47-54.
Guillouzo A, Morel F, Langouet S, Maheo K, Rissel M. 1997. Use of hepatocyte cultures for the study of hepatotoxic compounds. J Hepatol 26(Suppl. 2):73-80.
He Q, Osuchowski MF, Johnson VJ, Sharma RP. 2002. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: I induction of transforming growth factor beta1 and c-myc in liver with marginal effects on other genes. Planta Med 68:676-679.
Hinson JA, Pike SL, Pumford NR, Mayeux PR. 1998. Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice. Chem Res Toxicol 11:604-607.
Hoffman RM. 2004a. Imaging tumor angiogenesis with fluorescent proteins. Apmis 112:441-449.
Hoffman RM. 2004b. In vivo imaging with fluorescent proteins: the new cell biology. Acta Histochem 106:77-87.
Hoffmann GR. 1980. Genetic effects of dimethyl sulfate, diethyl sulfate, and related compounds. Mutat Res 75:63-129.
Holstege A, Anukarahanonta T, Yamamoto M, Koch HK, Kattermann R, Lesch R, Keppler D. 1981. Preventive effects of 5-fluorouridine and uridine on d-galactosamine-induced liver injury. Exp Mol Pathol 34:170-182.
Hsie AW, Brimer PA, Mitchell TJ, Gosslee DG. 1975. The dose-response relationship for ethyl methanesulfonate-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells. Somatic Cell Genet 1:247-261.
Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. 2004. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101:4477-4482.
Jaeschke H. 1990. Glutathione disulfide formation and oxidant stress during acetaminophen-induced hepatotoxicity in mice in vivo: the protective effect of allopurinol. J Pharmacol Exp Ther 255:935-941.
Jin J, Yang J, Gao Z, Yu Y. 2004. Proteomic analysis of cellular responses to low concentration N-methyl-N'-nitro-N-nitrosoguanidine in human amnion FL cells. Environ Mol Mutagen 43:93-99.
Johnson FH, Shimomura O. 1972. Enzymatic and nonenzymatic bioluminescence. Photophysiology 7:275-334.
Johnson VJ, Osuchowski MF, He Q, Sharma RP. 2002. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: II. alterations in thymic differentiation correlate with changes in c-myc gene expression. Planta Med 68:961-965.
Kasravi FB, Wang L, Wang XD, Molin G, Bengmark S, Jeppsson B. 1996. Bacterial translocation in acute liver injury induced by D-galactosamine. Hepatology 23:97-103.
Kassel DB. 2004. Applications of high-throughput ADME in drug discovery. Curr Opin Chem Biol 8:339-345.
Kenseth JR, Coldiron SJ. 2004. High-throughput characterization and quality control of small-molecule combinatorial libraries. Curr Opin Chem Biol 8:418-423.
Keppler D, Decker K. 1969. Studies on the mechanism of galactosamine-1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem 10:219-225.
Kittur S, Wilasrusmee S, Pedersen WA, Mattson MP, Straube-West K, Wilasrusmee C, Lubelt B, Kittur DS. 2002. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J Mol Neurosci 18:265-269.
Klungland A, Laake K, Hoff E, Seeberg E. 1995. Spectrum of mutations induced by methyl and ethyl methanesulfonate at the hprt locus of normal and tag expressing Chinese hamster fibroblasts. Carcinogenesis 16:1281-1285.
Knight TR, Kurtz A, Bajt ML, Hinson JA, Jaeschke H. 2001. Vascular and hepatocellular peroxynitrite formation during acetaminophen toxicity: role of mitochondrial oxidant stress. Toxicol Sci 62:212-220.
Kovalchuk I, Kovalchuk O, Hohn B. 2000. Genome-wide variation of the somatic mutation frequency in transgenic plants. Embo J 19:4431-4438.
Kravchenko LV, Avren'eva LI, Tutel'ian VA. 2000. Effects of bioflavonoids on the toxicity of T-toxin in rats. A biochemical study. Vopr Pitan 69:20-23.
Krieg DR. 1963. Ethyl methanesulfonate-induced reversion of bacteriophage T4rII mutants. Genetics 48:561-580.
Krone PH, Blechinger SR, Evans TG, Ryan JA, Noonan EJ, Hightower LE. 2005. Use of fish liver PLHC-1 cells and zebrafish embryos in cytotoxicity assays. Methods 35:176-187.
Kurauchi K, Nakaguchi Y, Tsutsumi M, Hori H, Kurihara R, Hashimoto S, Ohnuma R, Yamamoto Y, Matsuoka S, Kawai S, Hirata T, Kinoshita M. 2005. In vivo visual reporter system for detection of estrogen-like substances by transgenic medaka. Environ Sci Technol 39:2762-2768.
Lam KS. 1997. Application of combinatorial library methods in cancer research and drug discovery. Anticancer Drug Des 12:145-167.
Lee WM. 2003a. Acute liver failure in the United States. Semin Liver Dis 23:217-226.
Lee WM. 2003b. Drug-induced hepatotoxicity. N Engl J Med 349:474-485.
Lee WM. 2004. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 40:6-9.
Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. 2003. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 37:336-339.
Liehr H, Grun M, Seelig HP, Seelig R, Reutter W, Heine WD. 1978. On the pathogenesis of galactosamine hepatitis. Indications of extrahepatocellular mechanisms responsible for liver cell death. Virchows Arch B Cell Pathol 26:331-344.
Lippincott-Schwartz J, Patterson GH. 2003. Development and use of fluorescent protein markers in living cells. Science 300:87-91.
Lipshutz GS, Gruber CA, Cao Y, Hardy J, Contag CH, Gaensler KM. 2001. In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. Mol Ther 3:284-292.
Liu Y. 1998. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene 215:159-169.
Ljubimova JY, Petrovic LM, Arkadopoulos N, Blanc P, Geller SA, Demetriou AA. 1997. Lack of hepatocyte growth factor receptor (c-met) gene expression in fulminant hepatic failure livers before transplantation. Dig Dis Sci 42:1675-1680.
Lu Q, Lemke G. 2001. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293:306-311.
Luo YQ, Wu MC, Cong WM. 1999. Gene expression of hepatocyte growth factor and its receptor in HCC and nontumorous liver tissues. World J Gastroenterol 5:119-121.
Ma PC, Maulik G, Christensen J, Salgia R. 2003. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22:309-325.
Maestrini E, Tamagnone L, Longati P, Cremona O, Gulisano M, Bione S, Tamanini F, Neel BG, Toniolo D, Comoglio PM. 1996. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci USA 93:674-678.
Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. 1999. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 163:6800-6809.
March JC, Rao G, Bentley WE. 2003. Biotechnological applications of green fluorescent protein. Appl Microbiol Biotechnol 62:303-315.
Masson S, Scotte M, Francois A, Coeffier M, Provot F, Hiron M, Teniere P, Fallu J, Salier JP, Daveau M. 1999. Changes in growth factor and cytokine mRNA levels after hepatectomy in rat with CCl(4)-induced cirrhosis. Am J Physiol 277:G838-846.
Matsumoto K, Nakamura T. 1996. Emerging multipotent aspects of hepatocyte growth factor. J Biochem (Tokyo) 119:591-600.
McCallum CM, Comai L, Greene EA, Henikoff S. 2000. Targeted screening for induced mutations. Nat Biotechnol 18:455-457.
McElroy WD, Seliger HH, White EH. 1969. Mechanism of bioluminescence, chemiluminescence and enzyme function in the oxidation of firefly luciferin. Photochem Photobiol 10:153-170.
Mesa ML, Carrizosa R, Martinez-Honduvilla C, Benito M, Fabregat I. 1996. Changes in rat liver gene expression induced by thioacetamide: protective role of S-adenosyl-L-methionine by a glutathione-dependent mechanism. Hepatology 23:600-606.
Meyers LL, Beierschmitt WP, Khairallah EA, Cohen SD. 1988. Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol Appl Pharmacol 93:378-387.
Michalopoulos GK, DeFrances MC. 1997. Liver regeneration. Science 276:60-66.
Mirsalis JC, Tyson CK, Loh EN, Steinmetz KL, Bakke JP, Hamilton CM, Spak DK, Spalding JW. 1985. Induction of hepatic cell proliferation and unscheduled DNA synthesis in mouse hepatocytes following in vivo treatment. Carcinogenesis 6:1521-1524.
Mourelle M, Muriel P, Favari L, Franco T. 1989. Prevention of CCL4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 3:183-191.
Muller K, Kasper P, Muller L. 1993. An assessment of the in vitro hepatocyte micronucleus assay. Mutat Res 292:213-224.
Muriel P, Garciapina T, Perez-Alvarez V, Mourelle M. 1992. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 12:439-442.
Nguyen VT, Morange M, Bensaude O. 1988. Firefly luciferase luminescence assays using scintillation counters for quantitation in transfected mammalian cells. Anal Biochem 171:404-408.
Nygaard O, Eldjarn L, Nakken KF. 1954. Studies on the metabolism of thioacetamide-S35 in the intact rat. Cancer Res 14:625-628.
Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A. 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56-67.
Paine AJ, Hockin LJ. 1982. The maintenance of cytochrome P-450 in liver cell culture: recent studies on P-450 mediated mechanisms of toxicity. Toxicology 25:41-45.
Paris S, Sesboue R. 2004. Metastasis models: the green fluorescent revolution? Carcinogenesis 25:2285-2292.
Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, Vande Woude GF. 1986. Mechanism of met oncogene activation. Cell 45:895-904.
Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. 1987. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA 84:6379-6383.
Parra M, Lluis F, Miralles F, Caelles C, Munoz-Canoves P. 2000. The cJun N-terminal kinase (JNK) signaling pathway mediates induction of urokinase-type plasminogen activator (uPA) by the alkylating agent MNNG. Blood 96:1415-1424.
Porter WR, Gudzinowicz MJ, Neal RA. 1979. Thioacetamide-induced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat. J Pharmacol Exp Ther 208:386-391.
Porter WR, Neal RA. 1978. Metabolism of thioacetamide and thioacetamide S-oxide by rat liver microsomes. Drug Metab Dispos 6:379-388.
Prasher DC. 1995. Using GFP to see the light. Trends Genet 11:320-323.
Prasher DC, Eckenrode VK, Ward WW, Prendergast FG, Cormier MJ. 1992. Primary structure of the Aequorea victoria green-fluorescent protein. Gene 111:229-233.
Rainone F. 2005. Milk thistle. Am Fam Physician 72:1285-1288.
Ratanasavanh D, Baffet G, Latinier MF, Rissel M, Guillouzo A. 1988. Use of hepatocyte co-cultures in the assessment of drug toxicity from chronic exposure. Xenobiotica 18:765-771.
Ray SD, Sorge CL, Raucy JL, Corcoran GB. 1990. Early loss of large genomic DNA in vivo with accumulation of Ca2+ in the nucleus during acetaminophen-induced liver injury. Toxicol Appl Pharmacol 106:346-351.
Ribo JM, Canela M, Griful E. 2001. Repeatability and reproducibility of the luminescent bacteria bioassay. Environ Toxicol 16:127-135.
Rice BW, Cable MD, Nelson MB. 2001. In vivo imaging of light-emitting probes. J Biomed Opt 6:432-440.
Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F. 2002. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 65:135-150.
Saad B, Dakwar S, Said O, Abu-Hijleh G, Battah FA, Kmeel A, Aziazeh H. 2006. Evaluation of Medicinal Plant Hepatotoxicity in Co-cultures of Hepatocytes and Monocytes. Evid Based Complement Alternat Med 3:93-98.
Sadikot RT, Blackwell TS. 2005. Bioluminescence imaging. Proc Am Thorac Soc 2:537-540.
Sahai E, Wyckoff J, Philippar U, Segall JE, Gertler F, Condeelis J. 2005. Simultaneous imaging of GFP, CFP and collagen in tumors in vivo using multiphoton microscopy. BMC Biotechnol 23:5-14.
Salas VM, Corcoran GB. 1997. Calcium-dependent DNA damage and adenosine 3',5'-cyclic monophosphate-independent glycogen phosphorylase activation in an in vitro model of acetaminophen-induced liver injury. Hepatology 25:1432-1438.
Sega GA. 1984. A review of the genetic effects of ethyl methanesulfonate. Mutat Res 134:113-142.
Schriewer H, Badde R, Roth G, Rauen HM. 1973. The anti-hepatotoxic effect of silymarin on thioacetamide-induced liver damage. Arzneimittelforschung 23(Suppl):160.
Seol DW, Zarnegar R. 1998. Structural and functional characterization of the mouse c-met proto-oncogene (hepatocyte growth factor receptor) promoter. Biochim Biophys Acta 1395:252-258.
Shimomura O. 2005. The discovery of aequorin and green fluorescent protein. J Microsc 217:1-15.
Shinozuka H, Farber JL, Konishi Y, Anukarahanonta T. 1973. D-galactosamine and acute liver cell injury. Fed Proc 32:1516-1526.
Shiratori Y, Kawase T, Shiina S, Okano K, Sugimoto T, Teraoka H, Matano S, Matsumoto K, Kamii K. 1988. Modulation of hepatotoxicity by macrophages in the liver. Hepatology 8:815-821.
Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. 1999. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 290:1375-1383.
Spira B, Raw I. 2000. The effect of thioacetamide on the activity and expression of cytosolic rat liver glutathione-S-transferase. Mol Cell Biochem 211:103-110.
Stachlewitz RF, Seabra V, Bradford B, Bradham CA, Rusyn I, Germolec D, Thurman RG. 1999. Glycine and uridine prevent D-galactosamine hepatotoxicity in the rat: role of Kupffer cells. Hepatology 29:737-745.
Steele WJ, Busch H. 1966. Increased content of high molecular weight RNA fractions in nuclei and nucleoli of livers of thioacetamide-treated rats. Biochim Biophys Acta 119:501-509.
Stolf AM, D'Abronzo FH, Wang L, Salles JM, Andrade HF, Jr., Silva SM, Brentani R. 1976. Selection of albumin mRNA by thioacetamide. Biochem Biophys Res Commun 72:1576-1584.
Strom SC, Jirtle RL, Michalopoulos G. 1983. Genotoxic effects of 2-acetylaminofluorene on rat and human hepatocytes. Environ Health Perspect 49:165-170.
Tager M, Dietzmann J, Thiel U, Hinrich Neumann K, Ansorge S. 2001. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin. Free Radic Res 34:137-151.
Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM. 1999. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99:71-80.
Tamagnone L, Comoglio PM. 2000. Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol 10:377-383.
Tessier-Lavigne M, Goodman CS. 1996. The molecular biology of axon guidance. Science 274:1123-1133.
Tiegs G, Wolter M, Wendel A. 1989. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 38:627-631.
Tirmenstein MA, Nelson SD. 1989. Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. J Biol Chem 264:9814-9819.
Tirmenstein MA, Nelson SD. 1990. Acetaminophen-induced oxidation of protein thiols. Contribution of impaired thiol-metabolizing enzymes and the breakdown of adenine nucleotides. J Biol Chem 265:3059-3065.
Tsokos-Kuhn JO, Hughes H, Smith CV, Mitchell JR. 1988. Alkylation of the liver plasma membrane and inhibition of the Ca2+ ATPase by acetaminophen. Biochem Pharmacol 37:2125-2131.
Tyson CA, Hawk-Prather K, Story DL, Gould DH. 1983. Correlations of in vitro and in vivo hepatotoxicity for five haloalkanes. Toxicol Appl Pharmacol 70:289-302.
Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura N. 1995. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373:702-705.
Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T. 2004. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 64:6259-6265.
Vadi HV, Neal RA. 1981. Microsomal activation of thioacetamide-S-oxide to a metabolite(s) that covalently binds to calf thymus DNA and other polynucleotides. Chem Biol Interact 35:25-38.
Van de Waterbeemd H, Gifford E. 2003. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2:192-204.
Vogel G, Tuchweber B, Trost W, Mengs U. 1984. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 73:355-362.
Von Schonfeld J, Weisbrod B, Muller MK. 1997. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci 53:917-920.
Wang G, Yu Y, Chen X, Xie H. 2001. Low concentration N-methyl-N'-nitro-N-nitrosoguanidine activates DNA polymerase-beta expression via cyclic-AMP-protein kinase A-cAMP response element binding protein pathway. Mutat Res 478:177-184.
Wang Z, Wang G, Yang J, Guo L, Yu Y. 2003. Activation of protein kinase A and clustering of cell surface receptors by N-methyl-N'-nitro-N-nitrosoguanidine are independent of genomic DNA damage. Mutat Res 528:29-36.
Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS. 2002. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Med Sci Monit 8:BR439-443.
Wilson T, Hastings JW. 1998. Bioluminescence. Annu Rev Cell Dev Biol 14:197-230.
Xie X, Luo Z, Slawin KM, Spencer DM. 2004. The EZC-prostate model: noninvasive prostate imaging in living mice. Mol Endocrinol 18:722-732.
Yamauchi K, Yang M, Jiang P, Yamamoto N, Xu M, Amoh Y, Tsuji K, Bouvet M, Tsuchiya H, Tomita K, Moossa AR, Hoffman RM. 2005. Real-time in vivo dual-color imaging of intracapillary cancer cell and nucleus deformation and migration. Cancer Res 65:4246-4252.
Yang M, Baranov E, Wang JW, Jiang P, Wang X, Sun FX, Bouvet M, Moossa AR, Penman S, Hoffman RM. 2002. Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proc Natl Acad Sci USA 99:3824-3829.
Yang M, Li L, Jiang P, Moossa AR, Penman S, Hoffman RM. 2003. Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. Proc Natl Acad Sci USA 100:14259-14262.
Zarnegar R, Michalopoulos GK. 1995. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 129:1177-1180.
Zemanova L, Schenk A, Valler MJ, Nienhaus GU, Heilker R. 2003. Confocal optics microscopy for biochemical and cellular high-throughput screening. Drug Discov Today 8:1085-1093.
Zhang X, Yu Y, Chen X. 1994. Evidence for nontargeted mutagenesis in a monkey kidney cell line and analysis of its sequence specificity using a shuttle-vector plasmid. Mutat Res 323:105-112.
Zi X, Mukhtar H, Agarwal R. 1997. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun 239:334-339.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊